“Authorized” Generics Are “Legitimate Business Strategy,” Pfizer Says
Executive Summary
Pfizer views "authorized" generics as a sound business strategy following a drug's patent expiration, Senior Corporate Counsel Jeffrey Chasnow said during a Drug & Device Dialogue audio conference Oct. 7
You may also be interested in...
Pfizer’s “Swift Response” To Neurontin Generics Gives Greenstone 23% Share
Pfizer's Greenstone division held nearly a quarter of the generic gabapentin market share four days after the launch of AB-rated versions of Neurontin, Teva said in court filings
Pfizer’s “Swift Response” To Neurontin Generics Gives Greenstone 23% Share
Pfizer's Greenstone division held nearly a quarter of the generic gabapentin market share four days after the launch of AB-rated versions of Neurontin, Teva said in court filings
Congress Needs To Review “Authorized” Generics, Hatch And Waxman Agree
Congress will likely have to look at the issue of "authorized" generics, Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) said during an Oct. 6 Drug & Device Dialogue audio conference sponsored by FDC Reports and Polidais LLC